The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although antiplatelet therapy involving clopidogrel is a standard treatment for preventing cardiovascular events after coronary stent implantation, patients can display differential responses. Here, we assessed the effectiveness of clopidogrel on platelet function inhibition in subjects with and without type-2 diabetes and stable coronary artery disease. In addition, we investigated the correlation between platelet function and routine clinical parameters. METHODS: A total of 64 patients with stable coronary heart disease were enrolled in the study. Among these, 32 had known type-2 diabetes, whereas the remaining 32 subjects were non-diabetics (control group). A loading dose of 300 mg clopidogrel was given to clopidogrel-naïve patients (13 patients in the diabetes group and 14 control patients). All patients were given a daily maintenance dose of 75 mg clopidogrel. In addition, all patients received 100 mg ASA per day. Agonist-induced platelet aggregation measurements were performed on hirudin-anticoagulated blood using an impedance aggregometer (Multiple Platelet Function Analyzer, Dynabyte, Munich, Germany). Blood samples were drawn from the antecubital vein 24 h after coronary angiography with percutaneous coronary intervention. The platelets were then stimulated with ADP alone or ADP and prostaglandin-E (ADP and ADP-PGE tests, respectively) in order to evaluate clopidogrel-mediated inhibition of platelet function. The effectiveness of ASA was measured by stimulation with arachidonic acid (ASPI test). In addition, maximal platelet aggregation was assessed via stimulation with thrombin receptor-activating peptide (TRAP test). RESULTS: Patients with diabetes exhibited significantly less inhibition of platelet function than patients without diabetes (ADP-PGE test p = 0.003; ASPI test p = 0.022). Administering a clopidogrel loading dose of 300 mg did not result in a lower level of ADP-PGE-induced platelet reactivity in comparison to the use of a 75 mg maintenance dose. Moreover, we observed that ADP-PGE-induced platelet inhibition was positively correlated with fasting blood glucose and HbA1c (p < 0.01). CONCLUSIONS: Patients with type-2 diabetes exhibited increased platelet reactivity compared to patients without diabetes despite combined treatment with clopidogrel and ASA. Using a loading dose of clopidogrel rather than small daily doses was not sufficient for adequately overcoming increased platelet reactivity in patients with type-2 diabetes, highlighting the need for more effective anti-platelet drugs for such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Erlinge, D., Varenhorst, C., Braun, O. Ö., James, S., Winters, K. J., Jakubowski, J. A., Brandt, J. T., Sugidachi, A., Siegbahn, A., & Wallentin, L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.068 · Cited by 215
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control
Osende, J. I., Badimon, J. J., Fuster, V., Herson, P., Rabito, P., Vidhun, R., Zaman, A., Rodriguez, O. J., Lev, E. I., Rauch, U., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01555-8 · Cited by 167 · cited 2×
“Furthermore, we showed that a reduction in HbA1c level was associated with a reduction in blood thrombogenicity [12].”
Self-citation
Cited by
Micro–RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor
Witkowski, M., Weithauser, A., Tabaraie, T., Steffens, D., Kränkel, N., Witkowski, M., Stratmann, B., Tschoepe, D., Landmesser, U., & Rauch-Kroehnert, U. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306094 · Cited by 79
Self-citationDarakjian, L., Deodhar, M., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094967 · Cited by 53
Witkowski, M., Witkowski, M., Saffarzadeh, M., Friebel, J., Tabaraie, T., Ta Bao, L., Chakraborty, A., Dörner, A., Stratmann, B., Tschoepe, D., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0993-z · Cited by 50
Self-citation
Metadata
- Authors
- Schuette, C., Steffens, D., Witkowski, M., Stellbaum, C., Bobbert, P., Schultheiss, H.-P., & Rauch, U.
- Venue
- Cardiovascular Diabetology
- Published
- 2015-02-03
- Volume
- 14
- Issue
- 1
- Pages
- 15-15
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2163711374
- Cited by
- 49
- References
- 3
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. https://app.cochat.ai/papers/10.1186/s12933-015-0182-7
- The paper
- Schuette, C., Steffens, D., Witkowski, M., Stellbaum, C., Bobbert, P., Schultheiss, H.-P., & Rauch, U. (2015). The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-015-0182-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.